Mathematics for understanding disease

被引:13
作者
Bies, R. R. [1 ]
Gastonguay, M. R. [3 ]
Schwartz, S. L. [2 ]
机构
[1] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA
[2] Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA
[3] Metrum Inst, Tariffville, CT USA
关键词
D O I
10.1038/clpt.2008.53
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The application of mathematical models to reflect the organization and activity of biological systems can be viewed as a continuum of purpose. The far left of the continuum is solely the prediction of biological parameter values, wherein an understanding of the underlying biological processes is irrelevant to the purpose. At the far right of the continuum are mathematical models, the purposes of which are a precise understanding of those biological processes. No models in present use fall at either end of the continuum. Without question, however, the emphasis in regards to purpose has been on prediction, e.g., clinical trial simulation and empirical disease progression modeling. Clearly the model that ultimately incorporates a universal understanding of biological organization will also precisely predict biological events, giving the continuum the logical form of a tautology. Currently that goal lies at an immeasurable distance. Nonetheless, the motive here is to urge movement in the direction of that goal. The distance traveled toward understanding naturally depends upon the nature of the scientific question posed with respect to comprehending and/or predicting a particular disease process. A move toward mathematical models implies a move away from static empirical modeling and toward models that focus on systems biology, wherein modeling entails the systematic study of the complex pattern of organization inherent in biological systems.
引用
收藏
页码:904 / 908
页数:5
相关论文
共 33 条
[1]  
BASSINGTHWAITE JB, 1994, FRACTAL PHYSL
[2]  
BERGMAN R, 2007, DIABETES, V56, P1
[3]   Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation [J].
Chan, Phylinda L. S. ;
Nutt, John G. ;
Holford, Nicholas H. G. .
PHARMACEUTICAL RESEARCH, 2007, 24 (04) :791-802
[4]   Drug treatment effects on disease progression [J].
Chan, PLS ;
Holford, NHG .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :625-659
[5]  
Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095
[6]   A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus [J].
de Winter, Willem ;
DeJongh, Joost ;
Post, Teun ;
Ploeger, Bart ;
Urquhart, Richard ;
Moules, Ian ;
Eckland, David ;
Danhof, Meindert .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (03) :313-343
[7]  
DEUTCH D, 1997, FABRIC REALITY
[8]   Nonlinear dynamics in Clinical Pharmacology: the paradigm of cortisol secretion and suppression [J].
Dokoumetzidis, A ;
Iliadis, A ;
Macheras, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (01) :21-29
[9]   Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation [J].
Frey, N ;
Laveille, C ;
Paraire, M ;
Francillard, M ;
Holford, NHG ;
Jochemsen, R .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (02) :147-157
[10]   FRACTAL MECHANISMS IN THE ELECTROPHYSIOLOGY OF THE HEART [J].
GOLDBERGER, AL .
IEEE ENGINEERING IN MEDICINE AND BIOLOGY MAGAZINE, 1992, 11 (02) :47-52